Guangzhou ImVin Pharmaceutical

Guangzhou ImVin Pharmaceutical is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of first-in-class and best-in-class therapies. The company focuses on four major therapeutic areas: ophthalmology, oncology, medical aesthetics, and anti-aging. Its lead product candidates include YY001, a recombinant botulinum toxin in Phase 3 trials for aesthetic indications, and QA102, a novel small molecule for dry age-related macular degeneration. ImVin's R&D strategy is driven by a team of globally recognized scientists and supported by prominent investors such as Hillhouse Capital and Qiming Venture Partners. The company aims to address significant unmet medical needs through innovative drug discovery and global clinical development.